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Laminin-111 Protein Therapy Reduces Muscle
Pathology and Improves Viability of a Mouse Model
of Merosin-Deficient Congenital Muscular DystrophyJachinta E. Rooney,* Jolie R. Knapp,*
Bradley L. Hodges,† Ryan D. Wuebbles,* and
Dean J. Burkin*
From the Department of Pharmacology,* Center for Molecular
Medicine, University of Nevada School of Medicine, Reno,
Nevada; and Prothelia Inc.,† Milford, Massachusetts
Merosin-deficient congenital muscular dystrophy type 1A
(MDC1A) is a lethal muscle-wasting disease that is caused
by mutations in the LAMA2 gene, resulting in the loss of
laminin-2protein.MDC1Apatients exhibit severemuscle
weakness from birth, are confined to a wheelchair, re-
quire ventilator assistance, and have reduced life expec-
tancy. There are currently no effective treatments or cures
for MDC1A. Laminin-2 is required for the formation of
heterotrimeric laminin-211 (ie, 2, 1, and 1) and
laminin-221 (ie, 2, 2, and 1), which are major constit-
uents of skeletalmuscle basal lamina. Laminin-111 (ie,1,
1, and1) is thepredominant laminin isoform in embry-
onic skeletal muscle and supports normal skeletal muscle
development in laminin-2–deficientmuscle but is absent
from adult skeletal muscle. In this study, we determined
whether treatmentwithEngelbreth-Holm-Swarm–derived
mouse laminin-111 protein could rescue MDC1A in the
dyW/mouse model. We demonstrate that laminin-111
protein systemically delivered to the muscles of
laminin-2–deficient mice prevents muscle pathology,
improves muscle strength, and dramatically increases
life expectancy. Laminin-111 also prevented apoptosis
in laminin-2–deficient mouse muscle and primary hu-
man MDC1A myogenic cells, which indicates a con-
served mechanism of action and cross-reactivity be-
tween species. Our results demonstrate that laminin-
111 can serve as an effective protein substitution
therapy for the treatment of muscular dystrophy in the
dyW/ mouse model and establish the potential for its
use in the treatment of MDC1A. (Am J Pathol 2012, 180:
1593–1602; DOI: 10.1016/j.ajpath.2011.12.019)
Merosin-deficient congenital muscular dystrophy type 1A
(MDC1A) is a devastating neuromuscular disease with pa-tients exhibiting profound hypotonia from birth, develop-
mental delay, and dysmyelinating neuropathy.1,2 Patients
are often confined to a wheelchair at a young age and
exhibit feeding problems and/or respiratory insufficiency,
and die as early as the first decade of life.1–4 There is
currently no effective treatment or cure for MDC1A.
MDC1A is caused by mutations in the LAMA2 gene
resulting in defects in the laminin-2 protein, which is a
critical component of the heterotrimeric extracellular ma-
trix proteins laminin-211 and laminin-221 (merosin).5,6
Laminin-111 (1, 1, 1) is the predominant laminin iso-
form in early embryonic skeletal muscle develop-
ment.7–13 Laminin-211 (2, 1, 1) and laminin-221 (2,
2, 1) replace laminin-111 to become the predominant
laminin isoforms in adult skeletal muscle.7–13 Laminin-
211 anchors myofibers to the extrajunctional basement
membrane and is an important component of peripheral
nerve basement membrane.11 Laminin-221 is enriched at
neuromuscular junctions and promotes efficient neurotrans-
mission.14 The loss of laminin-211/221 in MDC1A patients
and mouse models results in poor myofiber adhesion, in-
creased sarcolemmal fragility. and sensitivity to apopto-
sis.15–21 Defective muscle regeneration and myofiber loss
are also observed in laminin-2–deficient myofibers indicat-
ing that the laminin composition in the extracellular matrix
plays a critical role in muscle maintenance.15–21
Previous studies have shown laminin-111 protein ther-
apy can prevent muscle disease and improve myogenic
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cular dystrophy.22,23 Since muscle development in
MDC1A patients and laminin-2 deficient mice proceeds
normally due to the presence of laminin-111, we tested
the hypothesis that laminin-111 could serve as an effec-
tive protein substitution therapy for laminin-2 deficiency.
Our study demonstrates laminin-111 protein can be sys-
temically delivered to the basal lamina of skeletal muscle
and the presence of laminin-111 reduced the biochemi-
cal, histological, and functional deficits associated with
the loss of laminin-211/221. We also demonstrate that
laminin-111 prevents apoptosis in primary myogenic
cells from MDC1A patients. These results show laminin-
111 can serve as a potent protein substitution therapy in
dyW/ mice and suggests that recombinant human
laminin-111 may become an important new protein ther-
apeutic for the treatment of MDC1A.
Materials and Methods
Mice and Human Myogenic Cell Lines
The dyW/ mice were maintained on the same genetic
background as previously described.24 Animal experi-
ments were performed under an approved institutional
animal care and use committee protocol. De-identified
primary myoblast cell lines from MDC1A and control pa-
tients were obtained from Dr. Kathryn North, Children’s
Hospital at Westmead and University of Sydney. Re-
search using human primary myogenic cells was per-
formed under an approved institutional review board pro-
tocol from the University of Nevada, Reno, Office of
Human Research Protection.
Laminin-111
Laminin-111 (Sigma, St. Louis, MO) was slowly thawed
overnight at 4°C. Mice were treated with intramuscular
(i.m.) or intraperitoneal (i.p.) injections with Engelbreth-
Holm-Swarm (EHS)-derived natural mouse laminin-111.
For intramuscular injections, the tibialis anterior (TA) mus-
cle was injected once with 100 L of a 1.0 mg/mL solution
of laminin-111. For systemic injections, dyW/mice were
injected i.p. with 1.0 mg/mL laminin-111 at 10.0 mg/kg
per week for the duration of their lives.
Immunofluorescence
Tricep muscles were embedded in OCT and cryosec-
tioned as previously described.23 Laminin-2 was de-
tected with a 1:500 dilution of rabbit anti-laminin-2 (2G)
polyclonal antibody (a kind gift from Peter Yurchenco,
Department of Pathology, Robert Wood Johnson Medical
School, Piscataway, NJ). A rat anti-mouse laminin-1
monoclonal antibody (MAB1903; Chemicon International,
Temecula, CA) was used to detect mouse laminin-1.
Collagen VI was detected using a rabbit polyclonal anti-
body (AB6588; Abcam, Cambridge, MA) at 1:10,000.
Primary rabbit and rat antibodies were detected with a
1:500 dilution of fluorescein isothiocyanate (FITC)-conju-gated anti-rabbit or FITC-conjugated anti-rat secondary
antibodies, redundant with previous phraseredundant
with previous phrase respectively. Secondary-only anti-
body controls were included to test for specificity. Fluo-
rescence was observed with a Zeiss Axioskop 2 Plus
fluorescent microscope, and images were captured with
a Zeiss AxioCamHRc digital camera and Axiovision 4.1
software (Carl Zeiss, Oberkochen, Germany).
Immunoblot Detection of Laminin-1
Mice were treated weekly with 10.0 mg/kg/week laminin-
111 starting at 10 days of age. Serum was collected by
tail vein bleed at 8 weeks of age. TA muscles harvested
from 10-week-old animals were pulverized with a liquid
nitrogen–cooled mortar and pestle, and proteins were
extracted in radioimmunoprecipitation assay buffer [50
mmol/L HEPES (pH 7.4), 150 mmol/L NaCl, 1 mmol/L
Na3VO4, 10 mmol/L NaF, 0.5% Triton X-100, 0.5% NP50,
10% glycerol, 2 mmol/L PMSF, and a 1:200 dilution of
Protease Inhibitor Cocktail Set III, Calbiochem, San
Diego, CA]. Protein concentrations were quantified using
a Bradford assay (Bio-Rad, Hercules, CA), and reduced
samples (10 g of tissue and 12 L of serum) were
separated on a 6% polyacrylamide gel and transferred to
nitrocellulose. Laminin-1 was detected with a 1:1000
dilution of rat anti-mouse laminin-1 monoclonal antibody
(MAB1903; Chemicon International, Temecula, CA) over-
night followed by a goat anti–rat-IgG secondary antibody
(1:5000; Li-Cor Biosciences, Lincoln, NE) for 1 hour. The
blot was imaged with an Odyssey Imaging System (Li-
Cor Biosciences). Engelbreth-Holm-Swarm–derived nat-
ural mouse laminin-111 from Sigma was used as a pos-
itive control (0.5 g).
Histology
TA and tricep muscles were embedded in OCT and 10-m
cryosections (50 m apart) were cut using a CM1850
cryostat (Leica, Wetzlar, Germany) and placed on micro-
scope slides (Surgipath Medical Industries, Richmond, IL).
Tissue sections were stained with hematoxylin and eosin
(H&E) as previously described.23 Central myonuclei in re-
generating muscles were counted at 630 magnification
by bright-field microscopy. The number of central nuclei per
muscle fiber was determined by counting aminimum of 500
muscle fibers per animal. At least five animals from each
genotype were analyzed. In addition, the cross-sectional
areas were quantified from a minimum of 5000 muscle
fibers per group per time point. Results are reported as the
average myofiber cross-sectional area.
Masson’s Trichrome Staining
Paraffin-embedded tricep muscles were sectioned and
stained using a Masson’s Trichrome Staining Kit (Ameri-
can Master Tech Scientific, Lodi, CA). Images were cap-
tured at 400 magnification under bright field using a
Zeiss Axioskop 2 Plus fluorescent microscope, and im-
ages were captured with Zeiss AxioCamHRc digital cam-
era and Axiovision 4.1 software.
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Mice received 50 L (i.p.) of a 10.0 mg/mL solution of
sterile Evans Blue dye in sterile PBS per 10 g of body
weight intraperitoneally. Tricep muscles were harvested
and flash-frozen in liquid nitrogen 3 hours later. Ten-mi-
crometer cryosections were placed on microscope slides
and fixed in 4% paraformaldehyde. Muscle fibers were out-
lined by incubating tissue sections with Oregon Green-
488–conjugated WGA (2 g/mL; Molecular Probes, Carls-
bad, CA). A minimum of 500 fibers per animal were
counted to determine the percentage of muscle fibers
positive for Evans Blue dye. At least four animals from
each genotype were analyzed. Images were captured
and counted at 630 magnification.
Inflammatory Cell Infiltration
Cytotoxic T cells, monocytes, and macrophages were
detected with a FITC-conjugated rat anti-mouse CD8a,
CD11b antibodies (BD Pharmingen, San Diego, CA) or a
FITC-conjugated anti-mouse F4/80 (Bioscience, San
Diego, CA). Ten-micrometer sections were fixed in 4%
paraformaldehyde for 5minutes, washed in PBS three times
for 5 minutes each, blocked with 5% bovine serum albumin/
PBS for 1 hour, incubated with anti-CD8 antibody, anti-F4/
80, and anti-mouse F4/80 at 1:1000 dilution for 1 hour, and
washed in 1% bovine serum albumin/PBS three times for 5
minutes each. The sections were mounted in Vectashield
containing DAPI (Vector Laboratories, Burlingame, CA).
The ratio of the number of positively labeled cells to the
total number of nuclei was calculated for 20 random,
nonoverlapping microscopic fields per animal at 630
magnification and then averaged.
Hydroxyproline Assay
Hydroxyproline content was used to measure fibrosis in
diaphragm muscle as previously described.25 Briefly,
diaphragm muscles were weighed before being acid hy-
drolyzed at 130°C for 12 hours in 5N HCl (10 mg muscle
wet weight/mL). Triplicates of each sample and standard
hydroxyproline solution were used for the assay. Samples
and standards were mixed with an equal volume of so-
dium hydroxide (2N final concentration) and hydrolyzed
by autoclave at 120°C for 20 minutes. Oxidation was
performed at room temperature for 25 minutes by adding
450 L of chloramine-T to each sample and mixing gen-
tly. The chromophore was developed by adding 500 L of
Ehrlich’s aldehyde reagent to each sample and incubating
the samples at 65°C for 20 minutes. Absorbance was read
at 550 nm using a spectrophotometer, and the hydroxypro-
line content of each sample was calculated using the stan-
dard hydroxyproline curve and data analyzed using Graph-
Pad Prism (GraphPad Software, La Jolla, CA).
Apoptosis
Apoptosis in muscle was measured using a terminal deoxy-
nucleotidyltransferase-mediated dUTP nick-end labeling kit
(TUNEL) (DeadEnd Fluorometric TUNEL System; Promega,Madison, WI) following the manufacturer’s instructions. The
number of apoptotic myonuclei and total nuclei were
counted in 10-m tricep tissue sections. The percentage of
TUNEL-positive nuclei per 630 magnification field was
calculated per mouse and averaged for each genotype.
Apoptosis in primary myogenic cells from normal and
MDC1A patients were examined using a TUNEL assay.
Differentiating cultures of laminin-2–deficient and normal
humanmyoblast cells on 1% gelatin–coated Lab-Tek eight-
well chamber slides (Nalge-Nunc International, Penfield,
NY) were exposed to 100 nmol/L of mouse laminin-111 or
50 nmol/L human laminin-111 for 120 hours. After 120
hours, the DeadEnd Fluorometric TUNEL assay (Promega,
Madison, WI) was used to label apoptotic nuclei, following
the manufacturer’s instructions. The number of apoptotic
nuclei in each chamber was counted in quadruplicate and
expressed as a percentage of total nuclei.
Grip Strength
The forelimb grip strength was assessed using a SDI Grip
Strength System and a Chatillon DFE Digital Force Gauge
(San Diego Instruments, San Diego, CA) as previously de-
scribed.26 Mice were allowed to grasp a horizontal platform
with their forelimbs and then pulled backwards. Six consec-
utive tests were performed for each mouse, and the peak
tension (grams of force) was recorded and data averaged.
Detection of Antibodies to EHS LAM-111
Mouse antibodies against EHS laminin-111 (Invitrogen,
Carlsbad, CA) were detected by enzyme-linked immu-
nosorbent assay. Laminin-111 was diluted in coat buffer
(Thermo Fisher Scientific, Waltham, MA), incubated over-
night at 4°C in a 96-well plate, and blocked with Tris-
buffered saline containing 5% dry milk. Sera were diluted
1:100 through 1:6400 in Tris-buffered saline and added
to duplicate wells. Negative controls consisted of Tris-
buffered saline and sera from saline-treated and un-
treated mice. Positive controls consisted of mouse sera
previously identified as having an anti-EHS laminin-111 titer.
Mouse anti-laminin-111 antibody was detected with biotin-
conjugated goat anti-mouse Fab-specific IgG (1:20,000;
Sigma) and streptavidin-HRP (1:5000, Thermo Fisher Sci-
entific). All incubations were for 1 hour at room temperature
followed by three washes of Tris-buffered saline, 0.1%
Tween-20. Following color development (1-step TMB
Turbo; Thermo Fisher Scientific) the absorbance at 450 nm
was measured on a Bio-Mark microplate reader (Bio-Rad).
The mouse anti–laminin-111 titer was calculated as the di-
lution of sera at which the absorbance at 450 nm was
equivalent to that of saline-treated or untreated mice.
Survival and Weight Analysis
Female mice were allowed to age with frequent monitor-
ing for weight loss and/or any signs of pain, distress, or
illness. Due to the hindlimb neuropathy, fresh kibble was
placed on the base of each cage to ensure all animals
were able to feed. Weight loss of 10% over a 1-week
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humanely euthanized.
Activity Assays
Mobility assessments were made at 5, 10, 15, and 20
weeks of age. Mice were singly placed in a clean cage
and monitored for 5 minutes. During this time, periods of
moving about the cage, standing up on hind paws, and
digging were considered times of activity. The number of
stand ups was also recorded at this time for all animals
that were physically capable.
Statistical Analysis
Survival data from wild-type, PBS- and laminin-111–
treated dyW/ mice were analyzed using the Kaplan-
Meier method. Survival curves were generated by Graph-
Pad Prism (GraphPad Software) and data compared
using log-rank (Mandel-Cox) statistical tests. Compari-
sons between multiple groups were performed by one-
way analysis of variance for parametric data or by
Kruskal-Wallis one-way analysis of variance on ranks for
nonparametric data using SigmaStat1.0 software (Jandel
Corp., San Rafael, CA). A P value 0.05 was considered
statistically significant. All averaged data are reported as
the mean  SD.
Results
Laminin-111 Protein Can Be Systemically
Delivered to Muscle and Restores Viability to
Laminin-2–Deficient Mice
To investigate whether laminin-111 can substitute for the
loss of laminin-211/221, we first determined whether
laminin-111 protein could be delivered to the muscle of
dyW/ mice. Five-week-old female wild-type and
dyW/ mice were injected intraperitoneally with PBS or
laminin-111 at 10.0 mg/kg per week, and the presence of
laminin-1 and laminin-2 in the TA muscle was exam-
ined by immunofluorescence. As expected, significant
levels of laminin-2 were found in the TA muscle of wild-
type mice but were completely absent in PBS- and
laminin-111–treated dyW/muscle (Figure 1A). Laminin-
111 is only found during embryonic muscle development
and is not found in adult muscle.7–13 Immunofluores-
cence using anti–laminin-1 revealed that wild-type and
dyW/ muscle treated with PBS contained no laminin-
1. By contrast, the skeletal muscle of dyW/ mice that
received intraperitoneal injections of laminin-111 were
strongly positive for laminin-1 (Figure 1A), confirming
that laminin-111 protein can be delivered to the muscle of
dyW/ mice via systemic intraperitoneal administration.
Immunoblot detection of the laminin-1 protein in wild-
type mice, and dyW/ mice treated with PBS or laminin-
111 demonstrated that a 400-kDa laminin-1 band was
only found in the serum and TA muscle of dyW/ mice
treated with laminin-111 (Figure 1B). Laminin-1 was not
detected in serum or muscle of wild-type or PBS-treateddyW/ mice. The laminin-1 remained predominantly
intact, but fragments of immunoreactive material could
be seen on long exposures and by Coomassie Blue stain-
ing (data not shown). This result suggests that the 900-
kDa molecular weight of laminin-111 is not a barrier to
systemic distribution, and laminin-111 that is resident in
skeletal muscle is resistant to proteolytic degradation.
To determine whether treatment with laminin-111 pro-
tein can restore viability of laminin-2–deficient mice, the
longevity of female wild-type mice and dyW/ mice
treated weekly with PBS or 10.0 mg/kg natural mouse
laminin-111 were subjected to Kaplan-Meier survival
analysis (Figure 2A). Although wild-type mice had a nor-
mal life expectancy, the median survival of dyW/ mice
treated with PBS was 82.5 days, with the oldest animals
surviving to 140 days of age (Figure 2A). In dramatic
contrast, dyW/ mice injected weekly with 10.0 mg/kg
laminin-111 had a median survival of 291.5 days, repre-
senting a 3.5-fold increase in life expectancy. The oldest
laminin-111–treated dyW/ mouse survived beyond 18
Figure 1. Laminin-111 (LAM-111) can be systemically delivered to laminin-
2–deficient muscle. A: Immunofluorescence of TA muscle from 5-week-old
wild-type mice, and dyW/ mice treated with PBS or 10.0 mg/kg/week
laminin-111 to detect laminin-1 and -2 proteins. Laminin-2 is detected
within the extracellular matrix of wild-type mice but absent from the muscle
of dyW/ mice treated with PBS or laminin-111. Laminin-1 is absent in the
TA muscle of wild-type and dyW/ mice but present in the extracellular
matrix of laminin-111–treated dyW/ animals. Scale bar  20 m. B: Im-
munoblot detection of the laminin-1 protein in wild-type mice, and dyW/
mice treated with PBS or laminin-111 demonstrated that a 400-kDa
laminin-1 band was only found in the serum and TA muscle of dyW/mice
treated with laminin-111. Laminin-1 was not detected in serum or muscle of
wild-type or PBS-treated dyW/ mice.months of age (Figure 2A). Laminin-111–treated dyW/
es not
f age is
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(Figure 2B). These results indicate that laminin-111 can
significantly extend the life expectancy and appearance
of the dyW/ mouse model of MDC1A.
Laminin-111 Protein Therapy Improves Mobility
and Muscle Strength in Laminin-2–Deficient
Mice
To examine whether laminin-111 treatment prevented the
weight loss associated with laminin-2 deficiency, body
weights were assessed at 5, 10, 15, and 20 weeks of age
(Figure 3A). Compared to wild-type mice, dyW/ mice
treated with PBS exhibited a progressive reduction in
body weight at all ages (Figure 3A). Compared to wild-
type animals, laminin-111–treated dyW/ mice also ex-
hibited lower body weights at all ages, yet more effec-
tively maintained their weight compared to PBS-treated
dyW/ mice (Figure 3A).
The loss of laminin-221/221 in dyW/ mice can result
in reduced mobility.17,19,20,27,28 Analysis of the average
number of stand ups over a 5-minute period showed that
5-, 10-, 15-, and 20-week-old dyW/ mice treated with
PBS displayed a 4.3-, 3.4-, 3.6-, and sixfold reduction,
respectively, in stand-up activity compared to wild-type
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Figure 2. Laminin-111 (LAM-111) improves survival of dyW/mice. A: Kap
(n  20), and dyW/ mice treated weekly with laminin-111 (n  10). Trea
B: Image of a 10-week-old dyW/ mouse treated with PBS shows weight lo
dyW/ mouse treated weekly with 10.0 mg/kg laminin-111 is groomed, do
neuropathy. A dyW/ mouse treated weekly with laminin-111 at 60 weeks on  5, 20 weeks n  3; dyweek-old dyW/ mice treated with laminin-111 demon-
strated a 1.9-, 1.4-, 2.3-, and 2.7-fold increase, respec-
tively, in stand ups versus PBS-treated dyW/ animals
(Figure 3B).
We measured the forelimb peak muscle tension to
assess whether laminin-111 treatment results in improved
muscle force (Figure 3C). Analysis revealed that 5-, 10-,
15-, and 20-week-old dyW/ mice treated with PBS ex-
hibited a 2.8-, 3.3-, 3.4-, and 7.2-fold decrease in forelimb
force generation, respectively, compared to wild-type
mice (Figure 3C). At 5, 10, 15 and 20 weeks of age,
dyW/ mice treated with laminin-111 showed a 1.6-,
1.5-, 1.4-, and 1.7-fold increase in forelimb force gener-
ation, respectively, compared to PBS-treated dyW/
mice (Figure 3C).
Lastly, overall activity of each group was measured
over a 5-minute period (Figure 3D). At 5, 10, 15 and 20
weeks of age, dyW/ mice treated with PBS demon-
strated a 1.7-, 1.6-, 1.9-, and 2.4-fold decrease in activity,
respectively, compared to wild-type animals (Figure 3D).
At 5, 10, 15 and 20 weeks of age, dyW/ mice treated
weekly with laminin-111 protein showed a 1.4-, 1.5-, 1.7-,
and 1.8-fold increase in activity compared to PBS-treated
dyW/ mice (Figure 3D). The improvement in stand-up
activity, force generation, and overall activity in laminin-
111–treated dyW/ mice indicates that laminin-111 can
-111) improves muscle strength and activity of the dyW/ mouse model of
S treatment, dyW/ mice treated weekly with laminin-111 more effectively
. B: The number of stand ups over a 5-minute period in a new cage is reduced
PBS compared to wild-type mice from 5 to 20 weeks of age. Stand ups are
ted dyW/ animals compared to PBS treatment from 5 to 20 weeks of age. C:
duced in dyW/ mice treated with PBS compared to wild-type mice from 5 to
scle strength is maintained at a higher level in dyW/mice treated weekly with
ty in a 5-minute period is reduced in dyW/ mice treated with PBS compared
dyW/ mice treated weekly with laminin-111 is significantly improved com-
*P 0.05. Wild type: n 10; dyW/PBS: 5 and 10 weeks n 10, 15 weeks
/
r survival analysis of wild-type mice (n 10), dyW/mice treated with PBS
ith laminin-111 increases survival of dyW/ mice by 3.5-fold (P  0.0001).
of grooming, joint contractures, and peripheral neuropathy. A 10-week-old
exhibit joint contractures, maintains weight, and shows reduced peripheral
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found in laminin-211/221 deficiency.
Laminin-111 Protein Therapy Prevents Muscle
Pathology in Laminin-2–Deficient Mice
MDC1A is characterized by progressive muscle wasting
in which myofibers undergo delayed regeneration, apop-
tosis, atrophy, and fibrosis.2,9,15–20,27–31 To determine
whether laminin-111 prevented muscle pathology in
dyW/ mice, TA muscle sections from 5-week-old fe-
male dyW/ mice were subjected to H&E staining (Fig-
ure 4A). PBS-treated dyW/ mice demonstrated myofi-
ber size variation, mononuclear infiltrates, and 46% of
myofibers containing centrally located nuclei (Figure 4, A
and B). By contrast, 5-week-old dyW/mice treated with
laminin-111 exhibited a reduced mononuclear infiltration
and a 2.3-fold reduction in the number of TA myofibers
with centrally located nuclei (Figure 4, A and B). Evans
Blue dye uptake was used to examine whether laminin-
111 corrected the sarcolemmal fragility found in laminin-
2–deficient muscle. Compared to wild-type mice, 6.5%
of myofibers from PBS-treated dyW/ mice were Evans
Blue positive, wherease only 0.9% of myofibers from
laminin-111–treated dyW/ mice were Evans Blue posi-
tive, a 7.3-fold decrease (Figure 4, A and C).
MDC1A patients and dyW/ mice exhibit progressive
muscle wasting, including atrophic myofibers and myofi-
ber loss.2,15–20,27–31 Analysis of the cross-sectional area
of tricep myofibers revealed that the peak cross-sec-
tional area of wild-type myofibers was between 1100
and 1200 m2, whereas dyW/ mice treated with PBS
exhibited a peak cross-sectional area of 600 to 700
m2, representing an 50% decrease (Figure 4D). The
Figure 4. Laminin-111 (LAM-111) protein therapy prevents muscle degenera
laminin-111 into the TA muscle of 5-week-old female dyW/ mice reduced
with PBS. Scale bar  20 m. B: Intramuscular injections of laminin-111 in
centrally located nuclei (CLN). C: Intramuscular injections of laminin-111 into
compared to PBS. D: Systemic laminin-111 treatment reduced the number o
cross-sectional areas compared to PBS-treated animals. E: Systemic laminin-1
to PBS-treated animals. *P  0.05; **P  0.001.triceps of dyW/ mice treated with laminin-111 exhib-ited a broader cross-sectional peak range, from 700 to
1700 m2 (Figure 4D).
To examine whether laminin-111 prevented muscle
loss, all of the myofibers in the triceps muscle of 5-week-
old mice were counted. Compared to wild-type, the tricep
muscle of dyW/ mice treated with PBS showed a three-
fold decrease in the number of myofibers (Figure 4E). In
laminin-111–treated dyW/ mice, there were twofold more
myofibers in the triceps muscle compared with PBS-treated
animals (Figure 4E). The prevention of muscle atrophy and
myofiber loss associated with the absence of laminin-211/
221 is consistent with the observed reduction in centrally
nucleatedmyofibers. Collectively, these results indicate that
laminin-111 therapy improved sarcolemmal integrity and
ameliorates myofiber atrophy, inflammation, and degener-
ation associated with laminin-2 deficiency.
Laminin-111 Protein Therapy Prevents Fibrosis
in Laminin-2–Deficient Muscle
Reduced muscle function in MDC1A correlates with pro-
gressive levels of fibrosis.27 Immunofluorescence revealed
substantial collagen VI deposition in 5-week-old triceps
muscle of dyW/ mice treated with PBS, whereas laminin-
111 therapy resulted in near wild-type levels of muscle
collagen VI (Figure 5A). Masson’s trichrome staining con-
firmed our immunofluorescence observations.
We used a hydroxyproline assay to examine the extent
of fibrosis in the diaphragm. Compared to 10-week-old
wild-type diaphragm muscle, dyW/ mice treated with
PBS exhibit a 6.6-fold increase in hydroxyproline (Figure
5B). By contrast, dyW/ mice treated with laminin-111
exhibit a 1.9-fold reduction in hydroxyproline content
compared to dyW/ mice treated with PBS (Figure 5B).
loss in the dyW/ mouse model of MDC1A. A: Intramuscular injections of
gy and Evans Blue dye (EBD) uptake compared to dyW/ muscle treated
ek-old dyW/ TA muscle reduced the percentage of myofibers containing
old TA muscle reduced the percentage of Evans Blue dye–positive myofibers
ic myofibers in 5-week-old dyW/ triceps muscle and improved myofiber
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tently indicate that laminin-111 protein therapy substan-
tially reduces fibrosis in the skeletal muscles of the
dyW/ mouse model of MDC1A.
Laminin-111 Protein Therapy Prevents
Inflammation in the Muscle of
Laminin-2–Deficient Muscle
One hallmark of MDC1A muscle pathology is inflamma-
tion.30 The presence of T cells (CD8a), macrophages
(F4/80, CD11b), and monocytes (CD11b) was quantified
in the triceps muscle of laminin-111– and PBS-treated
dyW/ mice. Compared to 5-week-old wild-type mice,
dyW/ mice treated with PBS exhibited a 61-fold in-
crease in CD8a-positive cells (Figure 6A), a 47-fold in-
crease in CD11b-positive cells (Figure 6B), and a 32-fold
increase in F4/80-positive macrophages (Figure 6C).
Figure 5. Laminin-111 (LAM-111) protein therapy reduces fibrotic develop-
ment in dyW/ muscle. A: Immunofluorescence showing collagen VI in the
triceps muscles of 5-week-old mice. Loss of laminin-211/221 increases col-
lagen VI levels in the triceps muscle of dyW/ mice. Laminin-111 treatment
prevents the increase in collagen VI associated with fibrosis. Secondary
antibody control (2Ab ctrl) is FITC-conjugated anti-rabbit–only antibody.
Masson’s trichrome staining of triceps muscle shows laminin-111 treatment
reduces blue fibrotic deposition in dyW/ muscle. Scale bar  20 m. B:
Box and whiskers plot of hydroxyproline content in the diaphragm muscle
shows the increase in hydroxyproline in 10-week-old dyW/ diaphragm is
reduced by weekly treatment of laminin-111. **P  0.0013; ***P  0.0001;
and ****P  0.004. n  5 mice per genotype or treatment.Compared to PBS-treated dyW/ mice, the triceps fromlaminin-111–treated dyW/ mice demonstrated a 3.5-
fold reduction in the number of CD8a-positive cells (Fig-
ure 6A), a 2.5-fold reduction in CD11b-positive cells (Fig-
ure 6B), and a 12.8-fold reduction of F4/80-positive
macrophages (Figure 6C). Together, these results indi-
cate laminin-111 protein therapy reduced the inflamma-
tory infiltrates of laminin-2–deficient muscle.
Finally, we determined whether EHS (mouse) laminin-
111 elicited an immune response in dyW/ mice. Sera
from 10-week-old wild-type and dyW/mice treated with
PBS or laminin-111 were subjected to enzyme-linked im-
munosorbent assay to detect antibodies against the in-
jected protein. Our results show that mice treated weekly
with 10.0 mg/kg laminin-111 for 9 weeks did not elicit
an immune response to the exogenous protein (see
Supplemental Table S1 at http://ajp.amjpathol.org).
These data indicate the laminin-111 protein is unlikely
to evoke a strong immune response during long-term
administration.
Laminin-111 Prevents Apoptosis in Mouse
Muscle and Primary Myoblasts from MDC1A
Patients
The loss of muscle cell adhesion to the basal lamina in
laminin-2–deficient muscle results in elevated levels of
apoptosis.15–20 Compared to 5-week-old wild-type mice,
Figure 6. Laminin-111 (LAM-111) reduces inflammation in dyW/ muscle.
The number of CD8a-positive lymphocytes (A), CD11b-positive macro-
phages and monocytes (B), and F4/80-positive macrophages (C) in 5-week-
W/old dy triceps muscle is reduced by laminin-111 treatment. *P  0.05;
**P  0.001.
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ninefold increase in the number of TUNEL-positive mus-
cle nuclei (Figure 7A). In sharp contrast, dyW/ mice
treated with laminin-111 protein showed a reduction in
apoptosis to wild-type levels (Figure 7A).
We next examined whether the mechanism of laminin-
111 protein therapy is conserved between mouse and
human muscle. Primary myogenic cells isolated from
MDC1A patients were cultured in the absence of exoge-
nous extracellular matrix and then treated with 100
nmol/L mouse or human laminin-111 followed by assess-
ment of the number of apoptotic nuclei (Figure 7B). Com-
pared to normal human myogenic cells (MAK and PC1
cell lines), primary myoblasts from MDC1A patients
(PHM-1 and PHM-2) incubated without extracellular ma-
trix for 120 hours exhibited a 2.4- to 2.6-fold increase in
the number of apoptotic nuclei (Figure 7B). In contrast,
treatment with mouse or human laminin-111 protein re-
duced the number of apoptotic nuclei in PHM-1 and
PHM-2 MDC1A patient cells to that observed in normal
human myogenic cells (Figure 7B). Together, these re-
sults indicate laminin-111 protein therapy potently pre-
vents the onset of apoptosis in the muscle of the dyW/
mouse model of MDC1A, and that mouse and human
laminin-111 cross-react through a conserved mechanism
to prevent apoptosis in human MDC1A myoblasts.
Discussion
Mutations in the LAMA2 gene result in the loss or defec-
Figure 7. Laminin-111 (LAM-111) protein therapy prevents apoptosis in
mouse muscle and primary human myogenic cells. A: TUNEL assay shows
mouse laminin-111 reduces the number of apoptotic nuclei in the triceps
muscle of dyW/ mice. B: Primary human myogenic cells from MDC1A
patients (PHM-1 and PHM-2) exhibit higher levels of apoptosis compared to
myogenic cells from unaffected patients (MAK and PC1). Treatment with 100
nmol/L mouse or 50 nmol/L human laminin-111 reduced the number of
TUNEL-positive myogenic cells from MDC1A patients (PHM-1 and PHM-2) to
levels observed in primary cell lines from unaffected patients (MAK1 and
PC1) (n  4 replicates). *P  0.05, **P  0.001.tive laminin-211 (2,2,1) and laminin-221 (2,2,1)heterotrimers, which are the underlying cause of disease
in MDC1A.2,5,6 MDC1A patients manifest hypotonia,
feeding and/or respiratory difficulties, dysmyelinating
neuropathy, muscle atrophy, and limited eye move-
ment.1–4 Most MDC1A patients are unable to walk without
assistance and are confined to a wheelchair, and
changes in brain white matter can lead to an increased
likelihood of seizure-like activity.1–3,29 Given that there
are currently no effective treatments or cure for MDC1A,
there is clearly an unmet medical need for therapies for
this devastating neuromuscular disease.
Laminin-111 supports early embryonic myogenesis,
but laminin-111 is not present in adult skeletal mus-
cle.7–13 The laminin-1 and -2 chains are the most
closely related, and therefore, we hypothesized that
laminin-111 could act as a substitution protein therapy to
prevent disease progression in the dyW/ mouse model
of MDC1A. Weekly systemic delivery of EHS-derived
mouse laminin-111 protein to dyW/ mice beginning at
10 days of age resulted in localization of laminin-111 to
the basal lamina of skeletal muscles, reduced muscle
pathology, improved muscle strength and activity, and
resulted in a profound increase in survival. The affinity of
-dystroglycan for laminin-111 is marginally lower than its
affinity toward laminin-211, and the 71 integrin pos-
sesses a much higher affinity for laminin-111 than
laminin-211.32–35 Thus, mechanistically, laminin-111 can
sufficiently bind both laminin receptors in laminin-2–
deficient skeletal muscle and restore sarcolemmal integ-
rity and adhesion.
Loss of the contact between myofibers and laminin-
211/221 in the extracellular matrix also initiates pro-
gramed cell death in laminin-2–deficient muscle. The
reduction of apoptosis, muscle degeneration, and myo-
fiber loss following laminin-111 treatment in dyW/ mice
is consistent with other reports that demonstrate the res-
toration of cell adhesion in laminin-2 deficiency restores
prosurvival signaling in muscle.19,36 In addition, laminin-
111–mediated stabilization of myofibers in dyW/ mice
is consistent with the observed reductions in fibrosis and
inflammation. The observation that mouse and human
laminin-111 prevent apoptosis in human MDC1A myo-
blasts also indicates a conserved mechanism of action
for this therapeutic strategy in both mouse and patient
muscle cells. Given the interplay among apoptotic,
trophic, and fibrotic signaling cascades in muscle, a ben-
eficial correction in each disease endpoint suggests that
laminin-111 is promoting a broad-based improvement in
muscle function.
Although laminin-111 is not produced in adult skeletal
muscle, all humans produce laminin-111 as a component
of the kidney basement membrane.37,38 Thus, we antic-
ipate that MDC1A patients will elicit a minimal immune
response to intravenously delivered recombinant human
laminin-111. Indeed, dyW/ mice treated with EHS
mouse laminin-111 elicited no detectable anti–laminin-
111 antibodies. As a therapy for MDC1A, human laminin-
111 protein therapy should possess a better safety profile
versus human laminin-221/221 since most MDC1A pa-
tients would view some or all of the human laminin-211/
221 protein as foreign and immunogenic.
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of MDC1A has led to innovative approaches for the treat-
ment of this severe congenital muscular dystrophy, in-
cluding transgenic expression in mice of laminin-1,28,31
laminin-2,31,36 miniagrin,19,20 GalNAc transferase,24 in-
sulin-like growth factor 1,39 7 integrin,40 and the anti-
apoptotic protein Bcl-2.41 Doxycycline and omigapil,
which inhibit apoptotic pathways, and 3-methyladenine,
which blocks autophagy, have been shown to be effec-
tive in the dyW/ mouse model of MDC1A.17,42,43 How-
ever, drug-based approaches that inhibit apoptosis or
autophagy do not address the primary defect in cellular
adhesion. Among the approaches listed above, only a
laminin-based therapy will restore adhesion via -dys-
troglycan and the 71 integrin, and correct the sec-
ondary consequences of laminin-211/221 deficiency.
The laminin-1 and -2 cDNAs approach 10 kb in size,
which precludes their construction into existing lentivi-
ral or adeno-associated viral-based gene therapy vec-
tors. Among all nontransgenic therapies tested to date in
MDC1A mouse models,17,42,43 laminin-111 protein pro-
motes the longest extension of life and therefore offers
significant potential as a broad-based therapeutic for the
treatment of MDC1A.
Recently, protein therapy involving laminin-111, bigly-
can, and TAT-utrophin have shown efficacy in reducing
muscle pathology in the mdx mouse model of Duchenne
muscular dystrophy.22,23,44,45 In this study, we show that
laminin-111 protein therapy can substitute for laminin-
211/221 to reduce muscle disease progression in the
dyW/ mouse model of MDC1A. The ability of protein
molecules such as laminin-111, biglycan, IgM, or TAT-
utrophin to traverse the vasculature to the muscle basal
lamina may result from a combination of passive and
active transport mechanisms, transcytosis, or the in-
herent pathological “leakiness” of dystrophic myofi-
bers.44–49 Given that the molecular weight of a potential
therapeutic agent need not be a barrier to drug develop-
ment, an intervention for other genetic diseases involving
defects in extracellular matrix proteins may be similarly
amenable to protein therapies.
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